GlassScriptPhysician profile
Tara Rae Evans
NPI 1740792522
$1,298.83
in general payments reported to CMS, 2019-2025
15 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.23 · 2022: $253 · 2023: $173 · 2024: $623 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $419.14 | 2022-2024 | Jornay Pm |
| Corium, LLC | $144.91 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $134.20 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $133.18 | 2022-2024 | |
| Aytu Biopharma, INC. | $73.78 | 2024-2025 | Karbinal |
| Supernus Pharmaceuticals, INC. | $72.13 | 2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $62.41 | 2025 | Jornay Pm |
| Kaleo, INC. | $59.36 | 2022-2023 | Auvi-Q |
| Phadia US INC. | $57.62 | 2024-2025 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $40.87 | 2022 | |
| Cipher Pharmaceuticals US LLC | $26.41 | 2025 | Natroba, Spinosad |
| Ars Pharmaceuticals Operations, INC. | $24.66 | 2025 | Neffy |
| Cranial Technologies, INC | $19.94 | 2023 | Doc Band |
| Neurelis, INC. | $18.99 | 2022 | |
| Novo Nordisk INC | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.